The development of cancer immunotherapy for Immune checkpoint inhibitors (ICI) resistant cancers has been a challenge. Current ICI-based combination therapy strategies have achieved some, albeit limited, success. A deeper understanding of Tumor Immunity in the Micro Environment (TIME) biology in the IO (Immuno-oncology) will unveil next-generation therapeutic strategies. The dynamic functional interplay within TME brings important insights into the design of effective combinatorial strategies against cancer.
With the advent of novel genomics, computational tools, and understanding of the complex pathways, it has become obvious that the future of cancer therapy relies on effective . . .
Access the full-content and exclusive insights by registering to futurebridge.com.
Stay on top of your industry related trends and oppotunities.
Get insightful information access without any restrictions.
Learn about fundamental challenges confronted by your industry.
Gain access to all upcoming webinars and reply on-demand.
Share your focus area or question to engage with our Analysts through the Business Objectives service.Submit My Business Objective
Our long-standing clients include some of the worlds leading brands and forward-thinking corporations.
Tell us about your business objectives here
Share your key questions to connect with our analyst for a no-obligation consultation
Click here to see examples of business objectives